CD46

The FibroGen – AstraZeneca China Agreement for Roxadustat remains in place FibroGen to explore licensing opportunities for Roxadustat SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced today that FibroGen and AstraZeneca have agreed to terminate the U.S./RoW roxadustat collaboration agreement entered into on July 30, 2013, under which AstraZeneca held development and commercialization rights in the United States and other territories outside of China not licensed to Astellas Pharma Inc. Pursuant to a termination and transition agreement entered into between the parties, AstraZeneca is returning all U.S./RoW roxadustat rights to FibroGen (with the exception of South Korea) and providing certain assistance during a transition period. FibroGen’s collaboration agreement with AstraZeneca for roxadustat in China remains in place and roxadustat remains the leader in China by brand value share in the chronic kidney disease (CKD) anemia category. In the event FibroGen subsequently monetizes or commercializes roxadustat in the territories formerly licensed under the U.S./RoW collaboration agreement, FibroGen will have certain financial obligations to AstraZeneca. “We continue to believe that roxadustat represents an important potential therapy for patients in the U.S. and other territories where it has not yet been approved,” said Thane Wettig, FibroGen Chief Executive Officer. “Based on the data presented at ASH 2023 investigating roxadustat for the treatment of anemia in patients with higher transfusion burden low-risk-MDS, we will be evaluating opportunities to bring this innovative medicine to patients through outreach to companies that may be interested in a product opportunity to address a disease with significant unmet need and attractive commercial potential.” About RoxadustatRoxadustat is an oral HIF-PH inhibitor that promotes erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, by improving iron absorption and mobilization and downregulation of hepcidin. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on-dialysis and not on-dialysis. AstraZeneca and FibroGen continue to collaborate on the development and commercialization of roxadustat in China. Roxadustat is in clinical development for chemotherapy-induced anemia and a Supplemental New Drug Application has been accepted by the China Health Authority. Several other licensing applications for roxadustat have been submitted by partners to regulatory authorities across the globe. Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in territories including Japan, Europe, Turkey, Russia, and the Commonwealth of Independent States, the Middle East, and South Africa. About FibroGen FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class oncology therapeutics. Pamrevlumab, an anti-CTGF fully-human monoclonal antibody, is in clinical development for the treatment of metastatic pancreas cancer and locally advanced unresectable pancreas cancer. FG-3246, an antibody-drug conjugate targeting CD46, is in Phase 1 development with potential applications in metastatic castrate resistant prostate cancer (mCRPC) and other CD46-expressing cancers. Roxadustat (爱瑞卓®, EVRENZO™) is in clinical development for chemotherapy-induced anemia and a Supplemental New Drug Application has been accepted by the China Health Authority. Roxadustat is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in CKD patients on-dialysis and not on-dialysis. FibroGen continues to research and develop its portfolio of novel oncology product candidates. For more information, please visit www.fibrogen.com. Forward-Looking Statements This release contains forward-looking statements regarding FibroGen’s strategy, future plans and prospects, including statements regarding the development and commercialization of roxadustat, including its commercial potential, and the potential safety and efficacy profile of roxadustat. These forward-looking statements include but are not limited to statements about FibroGen’s plans and objectives and typically are identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. FibroGen’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law. Contacts:FibroGen, Inc. Investors:David DeLucia, CFAVice President of Corporate FP&A / Investor Relationsir@fibrogen.com Media:Meichiel KeenanDirector, Investor Relations and Corporate Communicationsmedia@fibrogen.com

SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM ET. To register, click here. The event will feature Andrew Ko, MD (University of California San Francisco (UCSF), UCSF’s Helen Diller Family Comprehensive Cancer Center) and Vincent Picozzi, MD, MMM (Virginia Mason Digestive Disease and Cancer Institutes, Virginia Mason Medical Center), who will discuss the unmet medical need and current treatment landscape for pancreatic cancer, as well as the clinical development program for pamrevlumab*, a potential first-in-class monoclonal antibody targeting connective tissue growth factor (CTGF) for pancreatic cancer treatment. The event will include information on the mechanism of action of pamrevlumab as well as a review of the pre-clinical and Phase 1/2 data for pamrevlumab and the two ongoing trials: the innovative Precision Promise℠ Phase 2/3 trial being conducted by the Pancreatic Cancer Action Network (PanCAN) for metastatic pancreatic cancer, and the LAPIS Phase 3 trial in locally advanced pancreatic cancer. A live question and answer will follow the formal presentations. The second event in the series, to be scheduled at a later date, will include a review of the development program for FG-3246; a Phase 2 ready CD46 targeting antibody-drug conjugate (ADC) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This series is intended for investor audiences only. About Andrew Ko, MDAndrew Ko, MD completed his medical training at the Johns Hopkins School of Medicine (Baltimore, MD) and Beth Israel Hospital/Harvard Medical School (Boston, MA) before moving out west to complete his oncology training at Stanford University. He is currently a Professor of Medicine and Associate Chief of the Division of Hematology/Oncology at the University of California San Francisco (UCSF) and a member of UCSF’s Helen Diller Family Comprehensive Cancer Center. His primary clinical and research interests center on gastrointestinal cancers, with a particular emphasis on pancreatic and gastroesophageal malignancies. He has been responsible for developing and leading numerous clinical trials evaluating novel therapeutic strategies for these disease indications (ranging from novel cytotoxics to molecular targeted agents to immunotherapies) supported by industry collaborators, the National Cancer Institute, and various consortia/foundations. His work also entails efforts to identify individual patient/tumor characteristics that influence prognosis and response to specific therapies, including both tissue- and blood-based biomarkers. In addition to his role as Associate Editor for the Journal of Clinical Oncology since 2016, he is currently chair of the NCI’s Pancreatic Cancer Task Force; has served on the scientific program committee, grants committee, and specialty editorial board for the American Society of Clinical Oncology (ASCO); has played a leadership role within the GI Committee of the Alliance for Clinical Trials in Oncology to shepherd new trial concepts in pancreatic cancer through this national cooperative group; and sits on the National Comprehensive Cancer Network Pancreatic Cancer guidelines committee. About Vincent Picozzi, MD, MMMVincent Picozzi, MD, MMM is Director for the Pancreas Center of Excellence, Virginia Mason Digestive Disease and Cancer Institutes, Virginia Mason Medical Center. A summa cum laude, Phi Beta Kappa graduate from Yale University, Dr. Picozzi obtained his MD degree from Stanford University, did his internship and residency at Harvard University (Brigham and Women’s Hospital), and fellowships in hematology and oncology again at Stanford. He also holds a masters degree in medical management Delta Omega, from Tulane University. Dr. Picozzi was an instructor in hematology and oncology at Stanford for two years before joining Virginia Mason, where he has been for the past 38 years. Dr. Picozzi directs an active, comprehensive clinical and translational research program in pancreaticobiliary cancer at Virginia Mason. He has one of the largest pancreaticobiliary oncology practices in the United States. He has published over 150 papers and abstracts, and is currently the principal investigator of 3 registration trials in pancreatic cancer. Dr. Picozzi has been a featured speaker at virtually every major clinical oncologic meeting in the United States, including ASCO (the American Society of Clinical Oncology), ASH (the American Society of Hematology), ASTRO (the American Society of Therapeutic Radiation Oncology), Digestive Diseases Week, AHPBA (The American HepatoPancreaticobiliary Association), ACOS ( the American College of Surgeons), the Best of ASCO, the GI Oncology Symposium and the World Pancreas Symposium. Dr. Picozzi also has held a number of leadership positions with national and regional organizations, including ASCO, ASH, the American College of Surgeons Oncology Group (ACOSOG), the Pancreatic Cancer Action Network (PanCAN) (current board member and formal national chairman), the Pancreas Cancer Research Team (PCRT-Executive Committee), the Washington State Medical Oncology Society (WSMOS- Past President x 2), and the Providence Hospice of Seattle (Executive Board). He is currently the Co-Principal investigator of the Precision Promise Clinical Initiative, sponsored by GCAR, in metastatic pancreatic cancer. About PamrevlumabPamrevlumab is a potential first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in clinical development for the treatment of metastatic pancreatic cancer and locally advanced unresectable pancreatic cancer (LAPC). The U.S. Food and Drug Administration has granted Orphan Drug Designation for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC), and Fast Track designation to pamrevlumab for the treatment of patients with LAPC. Pamrevlumab has demonstrated a safety and tolerability profile that has supported ongoing clinical investigation in LAPC and metastatic pancreatic cancer. Pamrevlumab is an investigational drug and not approved for marketing by any regulatory authority. For information about our pamrevlumab studies please visit www.clinicaltrials.gov. About FibroGen FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Pamrevlumab, an anti-CTGF fully human monoclonal antibody, is in clinical development for the treatment of metastatic pancreatic cancer and locally advanced unresectable pancreatic cancer (LAPC). Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted for review by the China Health Authority. FibroGen recently expanded its research and development portfolio to include antibody-drug conjugate (ADC) and immunoncology product candidates for the treatment of solid tumors. For more information, please visit www.fibrogen.com. Forward-Looking Statements This release contains forward-looking statements regarding FibroGen’s strategy, future plans and prospects, including statements regarding its clinical programs and those of its partner, PanCAN. These forward-looking statements include, but are not limited to, statements regarding the potential and probability of success of FibroGen product candidates, and statements about FibroGen’s plans and objectives and typically are identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. FibroGen’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law. *Pamrevlumab is an investigational drug and not approved for marketing by any regulatory authority. FibroGen, Inc.Investors:David DeLucia, CFAVice President of Corporate FP&A / Investor Relationsir@fibrogen.com Media:Meichiel KeenanDirector, Investor Relations and Corporate Communicationsmedia@fibrogen.com

Topline data from two pivotal pamrevlumab pancreatic cancer trials on track to read out in 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer Third quarter net revenue of $40.1 million, an increase of 155% year over year Roxadustat sNDA accepted in China for chemotherapy-induced anemia Robust roxadustat volume growth of 37% in ChinaStrong execution of cost reduction plan reaffirming cash runway into 2026 SAN FRANCISCO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2023 and provided an update on the Company’s recent developments. “Today, we reported another quarter of strong roxadustat volume growth in China, achieving the highest ever value share, at 42%, in the anemia of CKD category,” said Thane Wettig, Chief Executive Officer, FibroGen. “The continued strength of our China business, sooner than expected realization of our corporate cost reduction efforts and our strong balance sheet provide us a cash runway into 2026. Over the next 12 months, we will obtain data read-outs from our two late-stage pancreatic cancer trials, start a Phase 2 metastatic castrate-resistant prostate cancer trial, and file two immuno-oncology INDs. These unique and exciting programs, combined with the quality of our talented colleagues, provide a strong foundation to create significant value for shareholders relative to our current valuation.” Recent Developments and Key Events of Third Quarter 2023: Appointed Thane Wettig as Chief Executive Officer.Supplemental New Drug Application (sNDA) accepted by the China Health Authority for roxadustat for the treatment of patients with chemotherapy-induced anemia (CIA). Expect approval decision of CIA in China in mid-2024.Successful implementation of cost reduction plan, now resulting in an expected reduction of total annualized expenses of $120 million.Reported negative topline results from the LELANTOS-2 Phase 3 study of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy (DMD).Presented Phase 3 data of roxadustat for CIA in patients with non-myeloid malignancies in an oral presentation at the European Society for Medical Oncology Congress 2023.FibroGen and its partners presented five roxadustat abstracts, including four poster presentations and one late-breaker poster presentation, at the recent American Society of Nephrology (ASN) Kidney Week 2023 conference.Presented preclinical data for the FG-3165 anti-Gal9 antibody program at the Society for Immunotherapy of Cancer Annual Meeting 2023. China Performance: Achieved third quarter net product revenue under U.S. GAAP from the sale of roxadustat in China of $29.4 million compared to $17.4 million in the third quarter of 2022, an increase of 69% year over year.Achieved third quarter total roxadustat net sales in China1 by FibroGen and the distribution entity (JDE) jointly owned by FibroGen and AstraZeneca of $77.1 million, compared to $59.0 million in the third quarter of 2022, an increase of 31% year over year, driven by 37% growth in volume.Roxadustat continues to be the number one brand based on value share in the anemia of chronic kidney disease market in China. Upcoming Milestones: Pamrevlumab Topline data from the LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer (LAPC) expected in 1Q 2024.Topline data from the PanCAN Precision PromiseSM Phase 2/3 study of pamrevlumab in metastatic pancreatic cancer expected in 1H 2024. Oncology Pipeline Expect topline clinical trial results from Phase 1 monotherapy trial of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting a novel epitope on CD46 for metastatic castration-resistant prostate cancer (mCRPC) by 1Q 2024.Anticipate the initiation of a Phase 2 trial of FG-3246 for mCRPC in 2H 2024.Anticipate the filing of two INDs: FG-3165 (anti-Gal9 antibody) in 1Q 2024 and FG-3175 (anti-CCR8 antibody) in 2H 2024. Financial: Total revenue for the third quarter of 2023 was $40.1 million, as compared to $15.7 million for the third quarter of 2022, an increase of 155% year over year.Net loss for the third quarter of 2023 was $63.6 million, or $0.65 net loss per basic and diluted share, compared to a net loss of $91.7 million, or $0.98 net loss per basic and diluted share one year ago.Restructuring charge for the third quarter of 2023 was $12.6 million, or $0.13 impact to net loss per basic and diluted share, resulting from the reduction in U.S. workforce announced in July 2023.At September 30, 2023, cash – defined as cash, cash equivalents, investments, and accounts receivable – was $283.0 million.We expect our cash, cash equivalents, investments, and accounts receivable to be sufficient to fund our operating plans into 2026. _________________________ 1 Total roxadustat net sales in China includes sales made by the distribution entity as well as FibroGen China’s direct sales, each to its own distributors. The distribution entity jointly owned by AstraZeneca and FibroGen is not consolidated into FibroGen’s financial statements. Conference Call and Webcast Details FibroGen will host a conference call and webcast today, Monday, November 6, 2023, at 5:00 PM Eastern Time to discuss financial results and provide a business update. Interested parties may access a live audio webcast of the conference call via the “Investor Relations” page of the Company’s website at www.fibrogen.com. To access the call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants to dial in to the conference call fifteen minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time at the following link (webcast replay). About PamrevlumabPamrevlumab is a potential first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase 3 clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer. The U.S. Food and Drug Administration has granted Orphan Drug Designation, and Fast Track designation to pamrevlumab for the treatment of patients with LAPC. Pamrevlumab has demonstrated a safety and tolerability profile that has supported ongoing clinical investigation in LAPC and metastatic pancreatic cancer. Pamrevlumab is an investigational drug and not approved for marketing by any regulatory authority. For information about our pamrevlumab studies please visit www.clinicaltrials.gov. About RoxadustatRoxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted by the China Health Authority. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD). Several other licensing applications for roxadustat have been submitted by partners, Astellas and AstraZeneca, to regulatory authorities across the globe, and are currently under review. Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in territories including Japan, Europe, Turkey, Russia, and the Commonwealth of Independent States, the Middle East, and South Africa. FibroGen and AstraZeneca are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in the U.S., China, and other markets not licensed to Astellas. About FibroGen FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and metastatic pancreatic cancer. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in CKD patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted by the China Health Authority. FibroGen recently expanded its research and development portfolio to include product candidates in oncology. For more information, please visit www.fibrogen.com. Forward-Looking Statements This release contains forward-looking statements regarding FibroGen’s strategy, future plans and prospects, including statements regarding the company’s financial performance, the development and commercialization of the company’s product candidates, the potential safety and efficacy profile of its product candidates, and its clinical programs. These forward-looking statements include, but are not limited to, statements under the caption “Upcoming Milestones”, statements regarding the expected cost reduction savings, the statement that FibroGen expects its cash, cash equivalents, investments, and accounts receivable to be sufficient to fund its operating plans into 2026, and statements about FibroGen’s plans and objectives and typically are identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. FibroGen’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law. Condensed Consolidated Balance Sheets(In thousands) September 30, 2023 December 31, 2022 (Unaudited) (1) Assets Current assets: Cash and cash equivalents$120,914 $155,700 Short-term investments 130,426 266,308 Accounts receivable, net 31,694 16,299 Inventory 40,696 40,436 Prepaid expenses and other current assets 40,378 14,083 Total current assets 364,108 492,826 Restricted time deposits 2,072 2,072 Long-term investments — 4,348 Property and equipment, net 14,512 20,605 Equity method investment in unconsolidated variable interest entity 4,534 5,061 Operating lease right-of-use assets 71,248 79,893 Other assets 3,952 5,282 Total assets$460,426 $610,087 Liabilities, stockholders’ equity and non-controlling interests Current liabilities: Accounts payable$19,220 $30,758 Accrued and other liabilities 170,986 219,773 Deferred revenue 7,325 12,739 Operating lease liabilities, current 11,884 10,292 Total current liabilities 209,415 273,562 Product development obligations 16,942 16,917 Deferred revenue, net of current 154,206 185,722 Operating lease liabilities, non-current 70,035 79,593 Senior secured term loan facilities, non-current 71,666 — Liability related to sale of future revenues, non-current 49,109 49,333 Other long-term liabilities 4,255 6,440 Total liabilities 575,628 611,567 Redeemable non-controlling interests 21,480 — Total stockholders’ deficit attributable to FibroGen (157,169) (21,447)Nonredeemable non-controlling interests 20,487 19,967 Total deficit (136,682) (1,480)Total liabilities, redeemable non-controlling interests and deficit$460,426 $610,087 (1) The condensed consolidated balance sheet amounts at December 31, 2022 are derived from audited financial statements. Condensed Consolidated Statements of Operations(In thousands, except per share data) Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 (Unaudited) Revenue: License revenue$2,649 $— $9,649 $22,590 Development and other revenue 6,775 2,453 15,825 19,672 Product revenue, net 29,390 17,359 77,439 59,495 Drug product revenue, net 1,320 (4,077) 17,701 4,610 Total revenue 40,134 15,735 120,614 106,367 Operating costs and expenses: Cost of goods sold 4,243 4,308 13,441 15,355 Research and development 61,194 75,182 231,158 235,163 Selling, general and administrative 25,573 29,902 91,029 90,722 Restructuring charge 12,606 — 12,606 — Total operating costs and expenses 103,616 109,392 348,234 341,240 Loss from operations (63,482) (93,657) (227,620) (234,873) Interest and other, net: Interest expense (5,022) (84) (10,464) (321)Interest income and other income (expenses), net 4,296 1,798 7,984 6,672 Total interest and other, net (726) 1,714 (2,480) 6,351 Loss before income taxes (64,208) (91,943) (230,100) (228,522)Provision for (benefit from) income taxes 84 114 (77) 250 Investment income in unconsolidated variable interest entity 677 407 2,023 1,293 Net loss$(63,615) $(91,650) $(228,000) $(227,479) Net loss per share - basic and diluted$(0.65) $(0.98) $(2.35) $(2.43) Weighted average number of common shares used to calculate net loss per share - basic and diluted 98,245 93,767 96,901 93,431 Contacts:FibroGen, Inc. Investors:David DeLucia, CFAVice President of Corporate FP&A / Investor Relationsddelucia@fibrogen.com Media:Meichiel KeenanDirector, Investor Relations and Corporate Communicationsmkeenan@fibrogen.com